95 related articles for article (PubMed ID: 16505415)
21. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
Nemunaitis J; Cunningham C; Buchanan A; Blackburn A; Edelman G; Maples P; Netto G; Tong A; Randlev B; Olson S; Kirn D
Gene Ther; 2001 May; 8(10):746-59. PubMed ID: 11420638
[TBL] [Abstract][Full Text] [Related]
22. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.
Nemunaitis J; Swisher SG; Timmons T; Connors D; Mack M; Doerksen L; Weill D; Wait J; Lawrence DD; Kemp BL; Fossella F; Glisson BS; Hong WK; Khuri FR; Kurie JM; Lee JJ; Lee JS; Nguyen DM; Nesbitt JC; Perez-Soler R; Pisters KM; Putnam JB; Richli WR; Shin DM; Walsh GL; Merritt J; Roth J
J Clin Oncol; 2000 Feb; 18(3):609-22. PubMed ID: 10653876
[TBL] [Abstract][Full Text] [Related]
24. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement.
Roth JA; Swisher SG; Merritt JA; Lawrence DD; Kemp BL; Carrasco CH; El-Naggar AK; Fossella FV; Glisson BS; Hong WK; Khurl FR; Kurie JM; Nesbitt JC; Pisters K; Putnam JB; Schrump DS; Shin DM; Walsh GL
Semin Oncol; 1998 Jun; 25(3 Suppl 8):33-7. PubMed ID: 9704675
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.
Ganly I; Kirn D; Eckhardt G; Rodriguez GI; Soutar DS; Otto R; Robertson AG; Park O; Gulley ML; Heise C; Von Hoff DD; Kaye SB
Clin Cancer Res; 2000 Mar; 6(3):798-806. PubMed ID: 10741699
[TBL] [Abstract][Full Text] [Related]
26. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.
Schuler M; Herrmann R; De Greve JL; Stewart AK; Gatzemeier U; Stewart DJ; Laufman L; Gralla R; Kuball J; Buhl R; Heussel CP; Kommoss F; Perruchoud AP; Shepherd FA; Fritz MA; Horowitz JA; Huber C; Rochlitz C
J Clin Oncol; 2001 Mar; 19(6):1750-8. PubMed ID: 11251006
[TBL] [Abstract][Full Text] [Related]
27. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
Antonia SJ; Mirza N; Fricke I; Chiappori A; Thompson P; Williams N; Bepler G; Simon G; Janssen W; Lee JH; Menander K; Chada S; Gabrilovich DI
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):878-87. PubMed ID: 16467102
[TBL] [Abstract][Full Text] [Related]
28. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).
Yen N; Ioannides CG; Xu K; Swisher SG; Lawrence DD; Kemp BL; El-Naggar AK; Cristiano RJ; Fang B; Glisson BS; Hong WK; Khuri FR; Kurie JM; Lee JJ; Lee JS; Merritt JA; Mukhopadhyay T; Nesbitt JC; Nguyen D; Perez-Soler R; Pisters KM; Putnam JB; Schrump DS; Shin DM; Walsh GL; Roth JA
Cancer Gene Ther; 2000 Apr; 7(4):530-6. PubMed ID: 10811470
[TBL] [Abstract][Full Text] [Related]
29. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.
Alvarez RD; Barnes MN; Gomez-Navarro J; Wang M; Strong TV; Arafat W; Arani RB; Johnson MR; Roberts BL; Siegal GP; Curiel DT
Clin Cancer Res; 2000 Aug; 6(8):3081-7. PubMed ID: 10955787
[TBL] [Abstract][Full Text] [Related]
30. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors.
Dummer R; Bergh J; Karlsson Y; Horowitz JA; Mulder NH; Huinink DTB ; Burg G; Hofbauer G; Osanto S
Cancer Gene Ther; 2000 Jul; 7(7):1069-76. PubMed ID: 10917210
[TBL] [Abstract][Full Text] [Related]
31. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach.
Cristofanilli M; Krishnamurthy S; Guerra L; Broglio K; Arun B; Booser DJ; Menander K; Van Wart Hood J; Valero V; Hortobagyi GN
Cancer; 2006 Sep; 107(5):935-44. PubMed ID: 16874816
[TBL] [Abstract][Full Text] [Related]
32. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.
Mukherjee S; Haenel T; Himbeck R; Scott B; Ramshaw I; Lake RA; Harnett G; Phillips P; Morey S; Smith D; Davidson JA; Musk AW; Robinson B
Cancer Gene Ther; 2000 May; 7(5):663-70. PubMed ID: 10830713
[TBL] [Abstract][Full Text] [Related]
33. [Clinical study of adenoviral mediated p53 gene therapy for non-small cell lung cancer in Japan].
Kagawa S; Fujiwara T; Tanaka N
Gan To Kagaku Ryoho; 2003 Feb; 30(2):193-7. PubMed ID: 12610865
[TBL] [Abstract][Full Text] [Related]
34. [A case of advanced non-small lung cancer responding to tumor suppressor p53 gene therapy].
Kagawa S; Ohtani S; Tanaka N; Fujiwara T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1788-90. PubMed ID: 15553716
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.
Triozzi PL; Allen KO; Carlisle RR; Craig M; LoBuglio AF; Conry RM
Clin Cancer Res; 2005 Jun; 11(11):4168-75. PubMed ID: 15930353
[TBL] [Abstract][Full Text] [Related]
36. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.
Mazzolini G; Alfaro C; Sangro B; Feijoó E; Ruiz J; Benito A; Tirapu I; Arina A; Sola J; Herraiz M; Lucena F; Olagüe C; Subtil J; Quiroga J; Herrero I; Sádaba B; Bendandi M; Qian C; Prieto J; Melero I
J Clin Oncol; 2005 Feb; 23(5):999-1010. PubMed ID: 15598979
[TBL] [Abstract][Full Text] [Related]
37. Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.
Tolcher AW; Hao D; de Bono J; Miller A; Patnaik A; Hammond LA; Smetzer L; Van Wart Hood J; Merritt J; Rowinsky EK; Takimoto C; Von Hoff D; Eckhardt SG
J Clin Oncol; 2006 May; 24(13):2052-8. PubMed ID: 16648505
[TBL] [Abstract][Full Text] [Related]
38. Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients.
Menon AG; Kuppen PJ; van der Burg SH; Offringa R; Bonnet MC; Harinck BI; Tollenaar RA; Redeker A; Putter H; Moingeon P; Morreau H; Melief CJ; van de Velde CJ
Cancer Gene Ther; 2003 Jul; 10(7):509-17. PubMed ID: 12833131
[TBL] [Abstract][Full Text] [Related]
39. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer.
Schuler M; Rochlitz C; Horowitz JA; Schlegel J; Perruchoud AP; Kommoss F; Bolliger CT; Kauczor HU; Dalquen P; Fritz MA; Swanson S; Herrmann R; Huber C
Hum Gene Ther; 1998 Sep; 9(14):2075-82. PubMed ID: 9759934
[TBL] [Abstract][Full Text] [Related]
40. [Effectiveness of recombinant adenovirus p53 injection on laryngeal cancer: phase I clinical trial and follow up].
Han DM; Huang ZG; Zhang W; Yu ZK; Wang Q; Ni X; Chen XH; Pan JH; Wang H
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2029-32. PubMed ID: 14703409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
